vs
Side-by-side financial comparison of HALOZYME THERAPEUTICS, INC. (HALO) and Vroom, Inc. (VRM). Click either name above to swap in a different company.
HALOZYME THERAPEUTICS, INC. is the larger business by last-quarter revenue ($451.8M vs $235.9M, roughly 1.9× Vroom, Inc.). HALOZYME THERAPEUTICS, INC. runs the higher net margin — -31.3% vs -59.8%, a 28.5% gap on every dollar of revenue. On growth, HALOZYME THERAPEUTICS, INC. posted the faster year-over-year revenue change (51.6% vs 12.9%). HALOZYME THERAPEUTICS, INC. produced more free cash flow last quarter ($217.6M vs $-108.8M). Over the past eight quarters, HALOZYME THERAPEUTICS, INC.'s revenue compounded faster (51.9% CAGR vs -49.5%).
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
Vroom, Inc. is a parent company of United Auto Credit Corporation (UACC) and CarStory. Previously, Vroom was a used car retailer and e-commerce company that let consumers buy, sell, and finance cars online. Vroom ceased e-commerce automotive sales operations on January 22, 2024.
HALO vs VRM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $451.8M | $235.9M |
| Net Profit | $-141.6M | $-141.1M |
| Gross Margin | 82.6% | 12.3% |
| Operating Margin | -20.6% | -11.5% |
| Net Margin | -31.3% | -59.8% |
| Revenue YoY | 51.6% | 12.9% |
| Net Profit YoY | -203.3% | -669.8% |
| EPS (diluted) | $-1.13 | $-80.66 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $451.8M | — | ||
| Q3 25 | $354.3M | — | ||
| Q2 25 | $325.7M | — | ||
| Q1 25 | $264.9M | — | ||
| Q4 24 | $298.0M | — | ||
| Q3 24 | $290.1M | — | ||
| Q2 24 | $231.4M | — | ||
| Q1 24 | $195.9M | — |
| Q4 25 | $-141.6M | — | ||
| Q3 25 | $175.2M | — | ||
| Q2 25 | $165.2M | — | ||
| Q1 25 | $118.1M | — | ||
| Q4 24 | $137.0M | — | ||
| Q3 24 | $137.0M | — | ||
| Q2 24 | $93.2M | — | ||
| Q1 24 | $76.8M | — |
| Q4 25 | 82.6% | — | ||
| Q3 25 | 84.4% | — | ||
| Q2 25 | 85.8% | — | ||
| Q1 25 | 81.7% | — | ||
| Q4 24 | 85.9% | — | ||
| Q3 24 | 83.0% | — | ||
| Q2 24 | 82.9% | — | ||
| Q1 24 | 85.5% | — |
| Q4 25 | -20.6% | — | ||
| Q3 25 | 61.5% | — | ||
| Q2 25 | 62.2% | — | ||
| Q1 25 | 53.4% | — | ||
| Q4 24 | 58.9% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 50.7% | — | ||
| Q1 24 | 48.8% | — |
| Q4 25 | -31.3% | — | ||
| Q3 25 | 49.5% | — | ||
| Q2 25 | 50.7% | — | ||
| Q1 25 | 44.6% | — | ||
| Q4 24 | 46.0% | — | ||
| Q3 24 | 47.2% | — | ||
| Q2 24 | 40.3% | — | ||
| Q1 24 | 39.2% | — |
| Q4 25 | $-1.13 | — | ||
| Q3 25 | $1.43 | — | ||
| Q2 25 | $1.33 | — | ||
| Q1 25 | $0.93 | — | ||
| Q4 24 | $1.06 | — | ||
| Q3 24 | $1.05 | — | ||
| Q2 24 | $0.72 | — | ||
| Q1 24 | $0.60 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $133.8M | $135.6M |
| Total DebtLower is stronger | $2.1B | $454.2M |
| Stockholders' EquityBook value | $48.8M | $127.7M |
| Total Assets | $2.5B | $1.5B |
| Debt / EquityLower = less leverage | 43.89× | 3.56× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $133.8M | — | ||
| Q3 25 | $419.7M | — | ||
| Q2 25 | $61.9M | — | ||
| Q1 25 | $176.3M | — | ||
| Q4 24 | $115.8M | — | ||
| Q3 24 | $154.3M | — | ||
| Q2 24 | $187.9M | — | ||
| Q1 24 | $164.6M | — |
| Q4 25 | $2.1B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.5B | — |
| Q4 25 | $48.8M | — | ||
| Q3 25 | $503.9M | — | ||
| Q2 25 | $332.7M | — | ||
| Q1 25 | $482.3M | — | ||
| Q4 24 | $363.8M | — | ||
| Q3 24 | $452.7M | — | ||
| Q2 24 | $289.4M | — | ||
| Q1 24 | $177.8M | — |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $1.8B | — |
| Q4 25 | 43.89× | — | ||
| Q3 25 | 3.00× | — | ||
| Q2 25 | 4.54× | — | ||
| Q1 25 | 3.13× | — | ||
| Q4 24 | 4.14× | — | ||
| Q3 24 | 3.32× | — | ||
| Q2 24 | 5.19× | — | ||
| Q1 24 | 8.44× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $219.0M | $-108.1M |
| Free Cash FlowOCF − Capex | $217.6M | $-108.8M |
| FCF MarginFCF / Revenue | 48.2% | -46.1% |
| Capex IntensityCapex / Revenue | 0.3% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $644.6M | $-536.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $219.0M | — | ||
| Q3 25 | $178.6M | — | ||
| Q2 25 | $99.7M | — | ||
| Q1 25 | $154.2M | — | ||
| Q4 24 | $178.5M | — | ||
| Q3 24 | $115.4M | — | ||
| Q2 24 | $55.8M | — | ||
| Q1 24 | $129.4M | — |
| Q4 25 | $217.6M | — | ||
| Q3 25 | $175.6M | — | ||
| Q2 25 | $98.1M | — | ||
| Q1 25 | $153.3M | — | ||
| Q4 24 | $175.4M | — | ||
| Q3 24 | $113.9M | — | ||
| Q2 24 | $53.2M | — | ||
| Q1 24 | $125.9M | — |
| Q4 25 | 48.2% | — | ||
| Q3 25 | 49.6% | — | ||
| Q2 25 | 30.1% | — | ||
| Q1 25 | 57.9% | — | ||
| Q4 24 | 58.9% | — | ||
| Q3 24 | 39.3% | — | ||
| Q2 24 | 23.0% | — | ||
| Q1 24 | 64.3% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.9% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 1.0% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 1.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.02× | — | ||
| Q2 25 | 0.60× | — | ||
| Q1 25 | 1.31× | — | ||
| Q4 24 | 1.30× | — | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 1.68× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
VRM
Segment breakdown not available.
